GALECTIN THERAPEUTICS INC (GALT) Stock News

USA - Nasdaq - NASDAQ:GALT - US3632252025 - Common Stock

5.73 USD

-0.03 (-0.52%)

Last: 11/28/2025, 7:34:43 PM

5.85 USD

+0.12 (+2.09%)

After Hours: 11/28/2025, 7:34:43 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GALT Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

2 months ago - By: Benzinga - Mentions: ADAP PRME GNPX HYPR ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025

2 months ago - By: Benzinga - Mentions: RIG CAN MBX BE ...

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

a year ago - By: BusinessInsider

News Image

GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q2 2024

3 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: The Motley Fool

Galectin Beats Q2 Loss Estimates

4 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update

5 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026

6 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

7 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

7 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

8 months ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: InvestorPlace

GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q2 2024

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

a year ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

1 years ago - By: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress